Business Context and Reporting Period
Company: Altimmune, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2019
Reporting Period: Fiscal quarter ended June 30, 2019
Context: The filing serves to announce the Company's financial results for the second quarter of 2019 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained within the referenced press release (Exhibit 99.1), which is not included in the input text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The document solely references the issuance of the quarterly results announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management issued a press release on August 13, 2019, regarding the Q2 2019 results.
Legal Disclaimer: The information furnished pursuant to Item 2.02 (including the press release) is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly incorporated by specific reference.
Risks and Contingencies: No specific risks or contingencies are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2019) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical development updates or pipeline milestones mentioned in the press release, as these are typical drivers for Altimmune's valuation.
- Confirm the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any forward-looking statements or guidance provided in the press release regarding future quarters.